Cardiovascular actions of human urotensin II - Considerations for hypertension

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 369, Issue 3, 2004, Pages 271-273

  Russell, Fraser D ^a   Molenaar, Peter ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cardiovascular; hU II; Human urotensin II; Hypertension; UT receptors

Indexed keywords

AMINO ACID RECEPTOR BLOCKING AGENT; NITRIC OXIDE; S 6716; UNCLASSIFIED DRUG; URANTIDE; UROTENSIN II;

BINDING AFFINITY; CARDIOVASCULAR RESPONSE; DRUG RECEPTOR BINDING; DRUG TARGETING; EDITORIAL; HUMAN; HYPERPOLARIZATION; HYPERTENSION; IMMUNOREACTIVITY; REGULATORY MECHANISM; SMOOTH MUSCLE TONE; VASOCONSTRICTION; VASODILATATION;

CARDIOVASCULAR AGENTS; HUMANS; HYPERTENSION; UROTENSINS;

EID: 1642390179     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-004-0876-y     Document Type: Editorial

References (23)

1. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, Ao Z, Disa J, Holmes SD, Stadel JM, Martin JD, Liu W-S, Glover GI, Wilson S, NcNulty DE, Ellis CE, Elshourbagy NA, Shabon U, Trill JJ, Hay DWP, Ohlstein EH, Bergsma DJ, Douglas SA (1999) Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401:282-286
2. Behm DJ, Johns DJ, Douglas SA (2004) Urotensin-II: a novel systemic hypertensive factor in the cat. Naunyn-Schmiedebergs Arch Pharmacol DOI 10.1007/s00210-004-0873-1
3. Böhm F, Pernow J (2002) Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol 135:25-27
4. Bottrill FE, Douglas SA, Hiley CR, White R (2000) Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol 130:1865-1870
5. Camarda V, Rizzi A, Calò G, Gendron G, Perron SI, Kostenis E, Zamboni P, Mascoli F, Regoli D (2002) Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents. Naunyn-Schmiedebergs Arch Pharmacol 365:141-149
6. Douglas SA, Sulpizio AC, Piercy V, Sarau HM, Ames RS, Aiyar NV, Ohlstein EH, Willette RN (2000) Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 131:1262-1274
7. Douglas SA, Tayara L, Ohlstein EH, Halawa N, Giaid A (2002) Congestive heart failure and expression of myocardial urotensin II. Lancet 359:1990-1997
8. Flohr S, Kurz M, Kostenis E, Brkovich A, Fournier A, Klabunde T (2002) Identification of nonpeptide urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. J Med Chem 45:1799-1805
9. Lim ML, Honisett SY, Sparkes CD, Komesaroff PA, Kompa A, Krum H (2004) Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure [abstract]. Clin Exp Pharmacol Physiol (in press)
10. MacLean MR, Stirrat DAA, Gallagher SM, Douglas SA, Ohlstein EH, Morecroft I, Polland K (2000) Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br J Pharmacol 130:201-204
11. Maguire JJ, Kuc RE, Davenport AP (2000) Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol 131:441-446
12. Ng LL, Loke I, O'Brien RJ, Squire IB, Davies JE (2002) Plasma urotensin in human systolic heart failure. Circulation 106:2877-2880
13. Opgaard OS, Nothacker H-P, Ehlert FJ, Krause DN (2000) Human urotensin II mediates vasoconstriction via an increase in inositol phosphates. Eur J Pharmacol 406:265-271
14. Patacchini R, Santiciloi P, Giuliani S, Grieco P, Novellino E, Rovero P, Maggi CA (2003) Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta. Br J Pharmacol 140:1155-1158
15. Richards AM, Nicholls MG, Lainchbury JG, Fisher S, Yandle TG (2002) Plasma urotensin II in heart failure. Lancet 360:545-546
16. Russell FD, Molenaar P, O'Brien DM (2001) Cardiostimulant effects of urotensin-II in human heart in vitro. Br J Pharmacol 132:5-9
17. Russell FD, Kearns P, Toth I (2003a) Investigation of urotensin-II converting enzyme activity in human cells and blood [abstract]. Proc Aust Soc Clin Exp Pharmacol Toxicol 10:35
18. Russell FD, Meyers D, Galbraith AJ, Bett N, Toth I, Kearns P, Molenaar P (2003b) Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol 285:H1576-H1581
19. Sauzeau V, Mellionnec EL, Bertoglio J, Scalbert E, Pacaud P, Loirand G (2001) Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res 88:1102-1104
20. Totsune K, Takahashi K, Arihara Z, Sone M, Satoh F, Ito S, Kimura Y, Sasano H, Murakami O (2001) Role of urotensin II in patients on dialysis. Lancet 358:810-811
21. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, Narumiya S (1997) Calcium sensitisation of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389:990-994
22. Wilkinson IB, Affolter JT, de Haas SL, Pellegrini MP, Boyd J, Winter MJ, Balment RJ, Webb DJ (2002) High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc Res 53:341-347
23. Zhang AY, Chen Y-F, Zhyang DX, Yi F-X, Qi J, Andrade-Gordon P, de Garavilla L, Li P-L, Zou A-P (2003) Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. Am J Physiol Renal Physiol 285:F792-F798